Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Rises 71.9%

Key Points

• Short interest surged 71.9% to 8.35 million shares as of September 30, representing about 5.9% of Inventiva’s outstanding stock and 3.3 days of average trading volume.
• Inventiva shares traded up 7.8% to $3.10, but remain well below their 50-day and 200-day moving averages of $4.11 and $4.50, respectively. The company reported a quarterly loss of $0.14 per share and $0.75 million in revenue.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $15.86 target price, while institutional investors own 19.06% of the company. Inventiva’s lead candidate, lanifibranor, is being evaluated in a Phase 3 trial for MASH.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 8,346,026 shares, an increase of 71.9% from the September 15th total of 4,853,831 shares. Based on an average daily trading volume, of 2,551,015 shares, the short-interest ratio is currently 3.3 days. Approximately 5.9% of the company's stock are sold short.

Inventiva Trading Up 7.8%

Shares of NASDAQ:IVA traded up $0.23 during trading on Thursday, reaching $3.10. 1,821,915 shares of the stock traded hands, compared to its average volume of 932,876. The stock has a 50-day moving average of $4.11 and a two-hundred day moving average of $4.50. Inventiva has a 52-week low of $2.82 and a 52-week high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. On average, equities research analysts forecast that Inventiva will post -0.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Platt Investment Counsel LLC purchased a new position in Inventiva in the 3rd quarter worth about $45,000. Engineers Gate Manager LP lifted its stake in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP bought a new position in Inventiva during the 1st quarter valued at about $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Inventiva during the 4th quarter valued at about $603,000. Hedge funds and other institutional investors own 19.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IVA. Wall Street Zen raised shares of Inventiva from a "sell" rating to a "hold" rating in a research report on Saturday, October 3rd. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an "overweight" rating for the company. Truist Financial lifted their price target on shares of Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Weiss Ratings lowered shares of Inventiva from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, October 8th. Finally, Piper Sandler restated an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Inventiva has an average rating of "Buy" and a consensus target price of $15.86.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.